Regarding cisplatin treatment, HDAC2 upregulation also significantly impaired cisplatin-induced tumor growth inhibition, while the combination of the HDAC inhibitor Entinostat with cisplatin reversed the cisplatin resistance induced by HDAC2 overexpression (Fig. 3H-J). This evidence concerns the gene HDAC2 and neoplasm.